|
1
|
Lin H, van den Esschert J, Liu C and van
Gulik TM: Systematic review of hepatocellular adenoma in China and
other regions. J Gastroenterol Hepatol. 26:28–35. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Villanueva A and Llovet JM: Targeted
therapies for hepatocellular carcinoma. Gastroenterology.
140:1410–1426. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Yang JD and Roberts LR: Hepatocellular
carcinoma: a global view. Nat Rev Gastroenterol Hepatol. 7:448–458.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Sanoff HK, Bernard S, Goldberg RM, et al:
Phase II study of capecitabine, oxaliplatin, and cetuximab for
advanced hepatocellular carcinoma. Gastrointest Cancer Res. 4:8–83.
2011.PubMed/NCBI
|
|
5
|
Okano J, Nagahara T, Matsumoto K and
Murawaki Y: The growth inhibition of liver cancer cells by
paclitaxel and the involvement of extracellular signal-regulated
kinase and apoptosis. Oncol Rep. 17:1195–1200. 2007.PubMed/NCBI
|
|
6
|
Caicedo-Granados EE, Wuertz BR, Marker PH,
Lee GS and Ondrey FG: The effect of indomethacin on paclitaxel
sensitivity and apoptosis in oral squamous carcinoma cells: the
role of nuclear factor-κB inhibition. Arch Otolaryngol Head Neck
Surg. 137:799–805. 2011.PubMed/NCBI
|
|
7
|
Sreekanth CN, Bava SV, Sreekumar E and
Anto RJ: Molecular evidences for the chemosensitizing efficacy of
liposomal curcumin in paclitaxel chemotherapy in mouse models of
cervical cancer. Oncogene. 30:3139–3152. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Kelly MG, Alvero AB, Chen R, et al: TLR-4
signaling promotes tumor growth and paclitaxel chemoresistance in
ovarian cancer. Cancer Res. 66:3859–3868. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Baines AT, Xu D and Der CJ: Inhibition of
Ras for cancer treatment: the search continues. Future Med Chem.
3:1787–1808. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Stronach EA, Chen M, Maginn EN, Agarwal R,
Mills GB, Wasan H and Gabra H: DNA-PK mediates AKT activation and
apoptosis inhibition in clinically acquired platinum resistance.
Neoplasia. 13:1069–1080. 2011.PubMed/NCBI
|
|
11
|
Luedde T and Schwabe RF: NF-κB in the
liver - linking injury, fibrosis and hepatocellular carcinoma. Nat
Rev Gastroenterol Hepatol. 8:108–118. 2011.
|
|
12
|
Luqman S and Pezzuto JM: NFkappaB: a
promising target for natural products in cancer chemoprevention.
Phytother Res. 24:949–963. 2010.PubMed/NCBI
|
|
13
|
Nogueira L, Ruiz-Ontañon P,
Vazquez-Barquero A, Moris F and Fernandez-Luna JL: The NFκB
pathway: a therapeutic target in glioblastoma. Oncotarget.
2:646–653. 2011.
|
|
14
|
Goss PE, Baptiste J, Fernandes B, Baker M
and Dennis JW: A phase I study of swainsonine in patients with
advanced malignancies. Cancer Res. 54:1450–1457. 1994.PubMed/NCBI
|
|
15
|
Santos FM, Latorre AO, Hueza IM, Sanches
DS, Lippi LL, Gardner DR and Spinosa HS: Increased antitumor
efficacy by the combined administration of swainsonine and
cisplatin in vivo. Phytomedicine. 18:1096–1101. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Sun JY, Yang H, Miao S, et al: Suppressive
effects of swainsonine on C6 glioma cell in vitro and in vivo.
Phytomedicine. 16:1070–1074. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
You N, Liu W, Zhong X, et al: Tg737
inhibition results in malignant transformation in fetal liver
stem/progenitor cells by promoting cell-cycle progression and
differentiation arrest. Mol Carcinog. 51:659–673. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Alves RC, Alves D, Guz B, et al: Advanced
hepatocellular carcinoma. Review of targeted molecular drugs. Ann
Hepatol. 10:21–27. 2011.PubMed/NCBI
|
|
19
|
Karikas GA: Anticancer and chemopreventing
natural products: some biochemical and therapeutic aspects. J BUON.
15:627–638. 2010.PubMed/NCBI
|
|
20
|
Tulsiani DR and Touster O: Swainsonine, a
potent mannosidase inhibitor, elevates rat liver and brain
lysosomal alpha-D-mannosidase, decreases Golgi alpha-D-mannosidase
II, and increases the plasma levels of several acid hydrolases.
Arch Biochem Biophys. 224:594–600. 1983. View Article : Google Scholar
|
|
21
|
van den Elsen JM, Kuntz DA and Rose DR:
Structure of Golgi alpha-mannosidase II: a target for inhibition of
growth and metastasis of cancer cells. EMBO J. 20:3008–3017.
2001.PubMed/NCBI
|
|
22
|
Shaheen PE, Stadler W, Elson P, Knox J,
Winquist E and Bukowski RM: Phase II study of the efficacy and
safety of oral GD0039 in patients with locally advanced or
metastatic renal cell carcinoma. Invest New Drugs. 23:577–581.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Yanagida K, Natsuka S and Hase S:
Structural diversity of cytosolic free oligosaccharides in the
human hepatoma cell line, HepG2. Glycobiology. 16:294–304. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Yeo TK, Yeo KT, Parent JB and Olden K:
Swainsonine treatment accelerates intracellular transport and
secretion of glycoproteins in human hepatoma cells. J Biol Chem.
260:2565–2569. 1985.PubMed/NCBI
|
|
25
|
Williams GH and Stoeber K: The cell cycle
and cancer. J Pathol. 226:352–364. 2012. View Article : Google Scholar
|
|
26
|
Fang J, Yu Z, Lian M, Ma H, Tai J, Zhang L
and Han D: Knockdown of zinc finger protein, X-linked (ZFX)
inhibits cell proliferation and induces apoptosis in human
laryngeal squamous cell carcinoma. Mol Cell Biochem. 360:301–307.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Hu W, Shen T and Wang MH: Cell cycle
arrest and apoptosis induced by methyl 3,5-dicaffeoyl quinate in
human colon cancer cells: Involvement of the PI3K/Akt and MAP
kinase pathways. Chem Biol Interact. 194:48–57. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Palumbo C, Bei R, Procopio A and Modesti
A: Molecular targets and targeted therapies for malignant
mesothelioma. Curr Med Chem. 15:855–867. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Rahbari NN, Mehrabi A, Mollberg NM, Müller
SA, Koch M, Büchler MW and Weitz J: Hepatocellular carcinoma:
current management and perspectives for the future. Ann Surg.
253:453–469. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Johansson M and Persson JL: Cancer
therapy: targeting cell cycle regulators. Anticancer Agents Med
Chem. 8:723–731. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Chang HR, Lian JD, Lo CW, Chang YC, Yang
MY and Wang CJ: Induction of urothelial proliferation in rats by
aristolochic acid through cell cycle progression via activation of
cyclin D1/cdk4 and cyclin E/cdk2. Food Chem Toxicol. 44:28–35.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Chen K, Perez-Stable C, D’Ippolito G,
Schiller PC, Roos BA and Howard GA: Human bone marrow-derived stem
cell proliferation is inhibited by hepatocyte growth factor via
increasing the cell cycle inhibitors p53, p21 and p27. Bone.
49:1194–1204. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Sayers TJ: Targeting the extrinsic
apoptosis signaling pathway for cancer therapy. Cancer Immunol
Immunother. 60:1173–1180. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Chowdhury I, Tharakan B and Bhat GK:
Current concepts in apoptosis: the physiological suicide program
revisited. Cell Mol Biol Lett. 11:506–525. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
He G and Karin M: NF-κB and STAT3 - key
players in liver inflammation and cancer. Cell Res. 21:159–168.
2011.
|
|
36
|
Deeb D, Gao X, Dulchavsky SA and Gautam
SC: CDDO-Me inhibits proliferation, induces apoptosis,
down-regulates Akt, mTOR, NF-kappaB and NF-kappaB-regulated
antiapoptotic and proangiogenic proteins in TRAMP prostate cancer
cells. J Exp Ther Oncol. 7:31–39. 2008.
|
|
37
|
Ma Y, Wang J, Liu L, et al: Genistein
potentiates the effect of arsenic trioxide against human
hepatocellular carcinoma: role of Akt and nuclear factor-κB. Cancer
Lett. 301:75–84. 2011.PubMed/NCBI
|
|
38
|
Matsubara J, Shimada Y, Kato K, et al:
Phase II study of bolus 5-fluorouracil and leucovorin combined with
weekly paclitaxel as first-line therapy for advanced gastric
cancer. Oncology. 81:291–297. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Fujiwara Y, Furukawa K, Shimada Y, et al:
Combination paclitaxel and inhibitor of nuclear factor κB
activation improves therapeutic outcome for model mice with
peritoneal dissemination of pancreatic cancer. Pancreas.
40:600–607. 2011.
|
|
40
|
Pasqualetti G, Ricciardi S, Mey V, Del
Tacca M and Danesi R: Synergistic cytotoxicity, inhibition of
signal transduction pathways and pharmacogenetics of sorafenib and
gemcitabine in human NSCLC cell lines. Lung Cancer. 74:197–205.
2011. View Article : Google Scholar : PubMed/NCBI
|
